Cultivation of myocardial tissue by using c-kit+ bone marrow mesenchymal stem cells and decellularized heart matrix

doi:10.3969/j.issn.2095-4344.2014.19.004

Abstract

Abstract:

BACKGROUND: Studies have found that c-kit+ bone marrow mesenchymal stem cells can differentiate into myocardial cells specifically, which may be the ideal seed cells.
OBJECTIVE: To investigate the feasibility of cultivation of myocardial tissue by using c-kit+ bone marrow mesenchymal stem cells and decellularized heart matrix.
METHODS: Heart tissues harvested from adult rats were decellularized for the following experiments. Primary rat bone marrow-derived mesenchymal stem cells were cultured in vitro. Until passage 8, bone marrow mesenchymal stem cells were enriched for c-kit and induced by 5 μmol/L 5-azacytidine for 2 weeks, and a second enrichment for the dihydropyridine receptor subunit α2δ1 was performed before analysis of cardiac differentiation or implantation into decellularized heart matrix for cultivation of myocardial tissue. Six weeks later, myocardial differentiation was identified by specific cardiac protein and action potential. Immunofluorescence staining was used to analysis neonatal myocardial tissue.
RESULTS AND CONCLUSION: Six weeks after the second enrichment, 60% bone marrow mesenchymal stem cells expressed cardiac troponin T, GATA binding protein 4, and connexin 43, and these cells could be induced to yield cardiac action potential, which was identified as cardiac differentiation. And when implanted into decellularized heart matrix, these cells could form myocardial tissue arranged regularly.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, mesenchymal stem cells, myocytes, cardiac

CLC Number:

R394.2

Zhang Guang-wei, Gu Tian-xiang, Guan Xiao-yu, Zhang Yu-hai. Cultivation of myocardial tissue by using c-kit+ bone marrow mesenchymal stem cells and decellularized heart matrix[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(19): 2975-2980.

Figures/Tables 1

References

[1] McMurray JJ.Clinical practice: Systolic heart failure.N Engl J Med. 2010;362(3):228-238.
[2] Renlund DG, Kfoury AG. When the failing end-stage heart is not end-stage. N Engl J Med. 2006;355(18):1922-1925.
[3] Adler ED, Goldfinger JZ, Kalman J, et al.Palliative care in the treatment of advanced heart failure. Circulation. 2009;120(25): 2597-2606.
[4] Hunt SA. Taking heart--cardiac transplantation past, present, and future. N Engl J Med. 2006;355(3):231-235.
[5] Almond CS, Gauvreau K, Thiagarajan RR, et al. Impact of ABO-incompatible listing on wait-list outcomes among infants listed for heart transplantation in the United States: a propensity analysis. Circulation. 2010;121(17):1926-1933.
[6] Slaughter MS, Rogers JG, Milano CA, et al.Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-2251.
[7] Terzic A, Nelson TJ. Regenerative medicine advancing health care 2020. J Am Coll Cardiol. 2010;55(20):2254-2257.
[8] Vunjak-Novakovic G, Tandon N, Godier A, et al.Challenges in cardiac tissue engineering. Tissue Eng Part B Rev. 2010; 16(2):169-187.
[9] Morritt AN, Bortolotto SK, Dilley RJ, et al. Cardiac tissue engineering in an in vivo vascularized chamber. Circulation. 2007;115(3):353-360.
[10] Bronshtein T, Au-Yeung GC, Sarig U,et al. A mathematical model for analyzing the elasticity, viscosity, and failure of soft tissue: comparison of native and decellularized porcine cardiac extracellular matrix for tissue engineering. Tissue Eng Part C Methods. 2013;19(8):620-630.
[11] Williams C, Quinn KP, Georgakoudi I, et al.Young developmental age cardiac extracellular matrix promotes the expansion of neonatal cardiomyocytes in vitro. Acta Biomater. 2014;10(1):194-204.
[12] Ye L, Zimmermann WH, Garry DJ, et al. Patching the heart: cardiac repair from within and outside. Circ Res. 2013; 113 (7):922-932.
[13] Tu W, Pindera MJ. Targeting the finite-deformation response of wavy biological tissues with bio-inspired material architectures. J Mech Behav Biomed Mater. 2013;28: 291-308.
[14] Buikema JW, Van Der Meer P, Sluijter JP, et al.Concise review: engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology. Stem Cells. 2013;31(12):2587-2598.
[15] Uygun BE, Yarmush ML, Uygun K. Application of whole-organ tissue engineering in hepatology. Nat Rev Gastroenterol Hepatol. 2012;9(12):738-744.
[16] Maher B. Tissue engineering: How to build a heart. Nature. 2013;499(7456):20-22.
[17] Kharaziha M, Nikkhah M, Shin SR, et al. PGS:Gelatin nanofibrous scaffolds with tunable mechanical and structural properties for engineering cardiac tissues. Biomaterials. 2013; 34(27):6355-6366.
[18] Tulloch NL, Murry CE. Trends in cardiovascular engineering: organizing the human heart. Trends Cardiovasc Med. 2013; 23(8):282-286.
[19] Lim SY, Sivakumaran P, Crombie DE, et al.Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering. Stem Cells Transl Med. 2013;2(9):715-725.
[20] Morritt AN, Bortolotto SK, Dilley RJ, et al. Cardiac tissue engineering in an in vivo vascularized chamber. Circulation. 2007;115(3):353-360.
[21] Ott HC, Matthiesen TS, Goh SK, et al. Perfusion- decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14(2):213-221.
[22] Buja LM, Vela D. Immunologic and inflammatory reactions to exogenous stem cells implications for experimental studies and clinical trials for myocardial repair. J Am Coll Cardiol. 2010;56(21):1693-1700.
[23] Laflamme MA, Murry CE. Heart regeneration. Nature. 2011; 473(7347):326-335.
[24] Zhang GW, Liu XC, Li-Ling J,et al. Mechanisms of the protective effects of BMSCs promoted by TMDR with heparinized bFGF-incorporated stent in pig model of acute myocardial ischemia. J Cell Mol Med. 2011; 15(5): 1075-1086.
[25] Ling SK, Wang R, Dai ZQ, et al. Pretreatment of rat bone marrow mesenchymal stem cells with a combination of hypergravity and 5-azacytidine enhances therapeutic efficacy for myocardial infarction. Biotechnol Prog.2011; 27(2):473- 482.
[26] He XQ, Chen MS, Li SH, et al.Co-culture with cardiomyocytes enhanced the myogenic conversion of mesenchymal stromal cells in a dose-dependent manner. Mol Cell Biochem. 2010; 339(1-2):89-98.
[27] Xu M, Wani M, Dai YS,et al. Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation. 2004; 110(17): 2658-2665.
[28] Kubo H, Berretta RM, Jaleel N, et al. c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. Clin Transl Sci.2009;2(1):26-32.
[29] Subramanyam P, Chang DD, Fang K, et al. Manipulating L-type calcium channels in cardiomyocytes using split-intein protein transsplicing. Proc Natl Acad Sci U S A. 2013 ;110(38): 15461-15466.
[30] Grajales L, García J, Banach K, et al. Delayed enrichment of mesenchymal cells promotes cardiac lineage and calcium transient development. J Mol Cell Cardiol. 2010; 48(4): 735-745.
[31] Robertson MJ, Dries-Devlin JL, Kren SM,et al. Optimizing recellularization of whole decellularized heart extracellular matrix. PLoS One. 2014;9(2):e90406.
[32] Ng SL, Narayanan K, Gao S, et al.Lineage restricted progenitors for the repopulation of decellularized heart. Biomaterials. 2011;32(30):7571-7580.
[33] Buikema JW, Van Der Meer P, Sluijter JP, et al. Concise review: Engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology. Stem Cells. 2013;31(12):2587-2598.
[34] Pozzobon M, Bollini S, Iop L,et al. Human bone marrow-derived CD133(+) cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant. 2010;19(10):1247-1260.
[35] Xing Y, Lv A, Wang L, Yan X, et al. Engineered myocardial tissues constructed in vivo using cardiomyocyte-like cells derived from bone marrow mesenchymal stem cells in rats. J Biomed Sci. 2012;19:6.
[36] Xin Y, Wang YM, Zhang H, et al. Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction. Artif Organs. 2010;34(3):215-222.
[37] Colazzo F, Sarathchandra P, Smolenski RT, et al. Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. Biomaterials. 2011;32(1):119-127.
[38] Valarmathi MT, Goodwin RL, Fuseler JW,A et al. 3-D cardiac muscle construct for exploring adult marrow stem cell based myocardial regeneration. Biomaterials. 2010; (12):3185-3200.
[39] Tan G, Shim W, Gu Y, et al.Differential effect of myocardial matrix and integrins on cardiac differentiation of human mesenchymal stem cells. Differentiation. 2010;79(4-5): 260-271.
[40] Halper J, Kjaer M.Basic components of connective tissues and extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, laminin, tenascins and thrombospondins. Adv Exp Med Biol. 2014;802:31-47.
[41] Balasubramanian S, Quinones L, Kasiganesan H, et al.β3-integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One. 2012;7(9):e45076.
[42] Kandalam V, Basu R, Moore L,et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011;124 (19):2094-2105.
[43] Stewart JA Jr, Gardner JD, Brower GL,et al.Temporal changes in integrin-mediated cardiomyocyte adhesion secondary to chronic cardiac volume overload in rats. Am J Physiol Heart Circ Physiol. 2014;306(1):H101-8.
[44] Chan CK, Rolle MW, Potter-Perigo S, et al.Differentiation of cardiomyocytes from human embryonic stem cells is accompanied by changes in the extracellular matrix production of versican and hyaluronan. J Cell Biochem. 2010;111(3):585-596.
[45] Li AH, Liu PP, Villarreal FJ, et al.Dynamic changes in myocardial matrix and relevance to disease: translational perspectives. Circ Res. 2014;114(5):916-927.
[46] Rienks M, Papageorgiou AP, Frangogiannis NG, et al.Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114(5):872-888.
[47] Chen CH, Wang SS, Wei EI,et al.Hyaluronan enhances bone marrow cell therapy for myocardial repair after infarction.Mol Ther. 2013;21(3):670-679.
[48] Lagendijk AK, Goumans MJ, Burkhard SB, et al.MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production.Circ Res. 2011;109(6): 649-657.
[49] Maioli M, Santaniello S, Montella A, et al.Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells.PLoS One. 2010;5(11):e15151.
[50] Yang MC, Chi NH, Chou NK, et al.The influence of rat mesenchymal stem cell CD44 surface markers on cell growth, fibronectin expression, and cardiomyogenic differentiation on silk fibroin - Hyaluronic acid cardiac patches.Biomaterials. 2010; 31(5):854-862.
[51] Yang MC, Wang SS, Chou NK, et al.The cardiomyogenic differentiation of rat mesenchymal stem cells on silk fibroin-polysaccharide cardiac patches in vitro.Biomaterials. 2009;30(22):3757-3765.
[52] Ventura C, Cantoni S, Bianchi F, et al.Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts.J Biol Chem. 2007;282(19):14243-14252.
[53] Ventura C, Maioli M, Asara Y, et al.Butyric and retinoic mixed ester of hyaluronan. A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells.J Biol Chem. 2004;279(22):23574-23579.
[54] Wheatley SC, Isacke CM.Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation.Cell Adhes Commun. 1995;3(3):217-230.